Treatment of acute and chronic diseases of the bronchopulmonary system that require reducing the viscosity of sputum, improving its discharge and expectoration.
active substance: xylometazoline hydrochloride;
1 ml of solution contains xylometazoline hydrochloride 1 mg;
Excipients: benzalkonium chloride, citric acid monohydrate, sodium citrate 2H2O, glycerin 85%, purified water.
Eucabal Dosage form
Main physical and chemical properties: clear colorless solution with a faint odor.
Means used in diseases of the nasal cavity. Anti-edema and other drugs for topical use in diseases of the nasal cavity. Sympathomimetics, simple drugs.
Code ATX R01A A07.
Eucabal Pharmacological properties
Xylometazoline is a sympathomimetic agent that acts on α-adrenergic receptors.
The effect of the drug begins a few minutes after application and lasts up to 12 hours. The drug causes narrowing of nasal blood vessels, reducing swelling of the nasal mucosa, its paranasal sinuses, thereby improving nasal breathing with nasal congestion and paranasal sinuses.
When applied topically, the drug is almost not absorbed, the concentration of xylometazoline in blood plasma is so low that it can not be determined by modern analytical methods.
Symptomatic treatment of nasal congestion with colds, hay fever, other allergic rhinitis, sinusitis.
To facilitate the outflow of secretions in diseases of the paranasal sinuses.
As adjunctive therapy in cases of otitis media (to eliminate mucosal edema).
To facilitate rhinoscopy.
Hypersensitivity to any component of the drug; dry inflammation of the nasal mucosa (dry rhinitis), acute coronary heart disease, hyperthyroidism, angle-closure glaucoma, transphenoidal hypophysectomy and surgery with exposure of the meninges in the anamnesis. Concomitant treatment with monoamine chloride (MAO) inhibitors and for 2 weeks after discontinuation.
Interaction with other medicinal products and other forms of interaction
MAO inhibitors: xylometazoline may potentiate the action of MAO inhibitors and induce hypertensive crises. Do not use xylometazoline in patients who have been taking or have been taking MAO inhibitors for the past two weeks.
Tri- and tetracyclic antidepressants: concomitant use of tri- or tetracyclic antidepressants and sympathomimetic drugs may increase the sympathomimetic effect of xylometazoline, so the simultaneous use of such drugs is not recommended.
When used in combination with β-blockers, the drug may cause bronchospasm or lower blood pressure.